Inventor
KOENIG JOHN R
US33 patents
⚠️ This page may combine multiple inventors who share the name “KOENIG JOHN R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ABBOTT LAB
16 patentsUS7015233B2Mar 21, 2006
Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
ABBOTT LAB39 citations96
US7129235B2Oct 31, 2006
Amides useful for treating pain
ABBOTT LAB32 citations92
US6933311B2Aug 23, 2005
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ABBOTT LAB24 citations92
US8026256B2Sep 27, 2011
Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
ABBOTT LAB11 citations84
US7998993B2Aug 16, 2011
TRPV1 antagonists
ABBOTT LAB8 citations83
US7902236B2Mar 8, 2011
Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof
ABBOTT LAB7 citations83
US7375126B2May 20, 2008
Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ABBOTT LAB9 citations83
US7622493B2Nov 24, 2009
Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
ABBOTT LAB6 citations73
US7504520B2Mar 17, 2009
Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof
ABBOTT LAB7 citations73
US7348343B2Mar 25, 2008
Amides useful for treating pain
ABBOTT LAB8 citations73
US7335678B2Feb 26, 2008
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
ABBOTT LAB8 citations73
US7074805B2Jul 11, 2006
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ABBOTT LAB10 citations73
US6831193B2Dec 14, 2004
Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
ABBOTT LAB8 citations72
US7037927B2May 2, 2006
Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
ABBOTT LAB3 citations62
US7595332B2Sep 29, 2009
Amides that inhibit vanilloid receptor subtype 1 (VR1)
ABBOTT LAB1 citations52
US7812019B2Oct 12, 2010
Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
ABBOTT LAB0 citations51
ABBVIE INC
4 patentsUS9969693B2May 15, 2018
6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
ABBVIE INC3 citations72
US9452986B2Sep 27, 2016
6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
ABBVIE INC5 citations72
US9783527B2Oct 10, 2017
Indazole ureas and method of use
ABBVIE INC1 citations48
US9777020B2Oct 3, 2017
Furo-3-carboxamide derivatives and methods of use
ABBVIE INC0 citations36
ABBVIE SARL
3 patentsUS10118916B2Nov 6, 2018
Modulators of cystic fibrosis transmembrane conductance regulator protein
ABBVIE SARL30 citations93
US9981910B2May 29, 2018
Substituted pyrrolidines and methods of use
ABBVIE SARL31 citations92
US10399940B2Sep 3, 2019
Substituted pyrrolidines and methods of use
ABBVIE SARL4 citations71
GOMTSYAN ARTHUR R
3 patentsUS8487116B2Jul 16, 2013
Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
GOMTSYAN ARTHUR R5 citations81
US8071762B2Dec 6, 2011
Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
GOMTSYAN ARTHUR R5 citations72
US8232309B2Jul 31, 2012
Prodrugs of compounds that inhibit TRPV1 receptor
GOMTSYAN ARTHUR R2 citations61